Ikarian Capital, LLC Viking Therapeutics, Inc. Transaction History

Ikarian Capital, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$47.39 - $80.2 $6.55 Million - $11.1 Million	138,262 New	138,262 $7.33 Million
Q1 2023 May 15, 2023	SELL	$8.08 - $17.33 $1.29 Million - $2.77 Million	-160,000 Reduced 78.76%	43,156 $718,000
Q4 2022 Feb 14, 2023	SELL	$2.72 - $9.4 $707,200 - $2.44 Million	-260,000 Reduced 56.14%	203,156 $1.91 Million
Q3 2022 Nov 14, 2022	SELL	$2.55 - $3.89 $948,903 - $1.45 Million	-372,119 Reduced 44.55%	463,156 $1.26 Million
Q2 2022 Aug 12, 2022	BUY	$2.11 - $3.15 $639,005 - $953,964	302,846 Added 56.88%	835,275 $2.41 Million
Q1 2022 May 13, 2022	BUY	$3.0 - $4.88 $95,361 - $155,120	31,787 Added 6.35%	532,429 $1.6 Million
Q3 2021 Nov 15, 2021	SELL	$5.58 - $7.04 $134,544 - $169,748	-24,112 Reduced 4.59%	500,642 $3.14 Million
Q2 2021 Aug 16, 2021	SELL	$5.19 - $6.73 $1.04 Million - $1.35 Million	-200,000 Reduced 27.6%	524,754 $3.14 Million
Q1 2021 May 17, 2021	BUY	$5.74 - $9.67 $4.16 Million - $7.01 Million	724,754 New	724,754 $4.58 Million
Q3 2020 Nov 16, 2020	SELL	$5.73 - $8.11 $6,641 - $9,399	-1,159 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$4.35 - $8.08 $543,750 - $1.01 Million	-125,000 Reduced 99.08%	1,159 $8,000
Q4 2019 Jan 31, 2020	BUY	$6.38 - $8.73 $804,894 - $1.1 Million	126,159 New	126,159 $1.01 Million

474

66.2M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.18B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.